These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9876818)

  • 1. Therapy of Candida infections: susceptibility testing, resistance, and therapeutic options.
    Klepser ME; Lewis RE; Pfaller MA
    Ann Pharmacother; 1998 Dec; 32(12):1353-61. PubMed ID: 9876818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on clinical antifungal susceptibility testing for Candida species.
    Lewis RE; Klepser ME; Pfaller MA
    Pharmacotherapy; 1998; 18(3):509-15. PubMed ID: 9620102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility testing of fungi and correlation with clinical outcome.
    Ghannoum MA
    J Chemother; 1997 May; 9 Suppl 1():19-24. PubMed ID: 9248959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
    Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
    Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of real-time fungal susceptibility on clinical practices.
    Magiorakos AP; Hadley S
    Curr Opin Infect Dis; 2004 Dec; 17(6):511-5. PubMed ID: 15640704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy.
    Lewis RE; Klepser ME
    Am J Health Syst Pharm; 1999 Mar; 56(6):525-33; quiz 534-5. PubMed ID: 10192687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological advances in the treatment of invasive candidiasis.
    Deck DH; Guglielmo BJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):137-49. PubMed ID: 16441215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neonatal Candida infections and the antifungal susceptibilities of the related Candida species].
    Altuncu E; Bilgen H; Cerikçioğlu N; Ilki A; Ulger N; Bakır M; Akman I; Ozek E
    Mikrobiyol Bul; 2010 Oct; 44(4):593-603. PubMed ID: 21063972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal resistance in pathogenic fungi.
    Perea S; Patterson TF
    Clin Infect Dis; 2002 Nov; 35(9):1073-80. PubMed ID: 12384841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antifungal susceptibility of Candida species isolated from patient with invasive fungal peritonitis and investigation on clinical breakpoints of itraconazole].
    Yamagishi Y; Terada M; Ohki E; Mikamo H
    Jpn J Antibiot; 2009 Oct; 62(5):415-34. PubMed ID: 20055119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of antifungal susceptibility testing in Candida isolates by Candifast and disk-diffusion method.
    Giri S; Kindo AJ
    Indian J Pathol Microbiol; 2014; 57(4):595-7. PubMed ID: 25308014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal drug resistance: limited data, dramatic impact?
    Rogers TR
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():7-11. PubMed ID: 16701982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azole resistance in neonatal intensive care units in Argentina.
    Giusiano G; Mangiaterra M; Rojas F; Gómez V
    J Chemother; 2005 Jun; 17(3):347-50. PubMed ID: 16038532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal resistance: the clinical front.
    Perfect JR
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 13):15-22. PubMed ID: 15682590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.
    Rex JH; Walsh TJ; Sobel JD; Filler SG; Pappas PG; Dismukes WE; Edwards JE
    Clin Infect Dis; 2000 Apr; 30(4):662-78. PubMed ID: 10770728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis].
    Viudes A; Cantón E; Pemán J; López-Ribot JL; Gobernado M
    Rev Esp Quimioter; 2002 Mar; 15(1):32-42. PubMed ID: 12582435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.
    Pinto PM; Weikert-Oliveira Rde C; Lyon JP; Cury VF; Arantes RR; Koga-Ito CY; Resende MA
    Microbiol Res; 2008; 163(5):579-85. PubMed ID: 16962755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study.
    Kim SH; Shin JH; Kim EC; Lee K; Kim MN; Lee WG; Uh Y; Lee HS; Lee MK; Jeong SH; Jung SI; Park KH; Lee JS; Shin MG; Suh SP; Ryang DW
    Med Mycol; 2009 May; 47(3):296-304. PubMed ID: 18668423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.